natgillin/translations-raw huggingface dataset:
For more information about treatment with Evarrest, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Za več informacij o zdravljenju z zdravilom Evarrest preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
Evarrest should only be used by experienced surgeons who will judge the amount to use based on the size and location of the bleeding area.
Zdravilo Evarrest lahko uporabljajo samo izkušeni kirurgi, ki bodo presodili, kakšno količino je primerno uporabiti glede na velikost in območje krvavečega mesta.
The Agency's Committee for Medicinal Products for Human Use (CHMP) noted that Evarrest was shown to be effective when used to stop bleeding in surgery and the product could be a suitable alternative to other products and techniques.
Odbor za zdravila za uporabo v humani medicini (CHMP) je menil, da je bilo zdravilo Evarrest učinkovito pri zaustavljanju krvavitev med operacijo in da bi lahko bilo primerna alternativa drugim zdravilom in tehnikam.
Evarrest should therefore only be used when standard methods for controlling bleeding are not sufficient.
Zato se lahko zdravilo Evarrest uporablja samo, kadar standardne metode za obvladovanje krvavitev niso dovolj učinkovite.
During surgery, the patches are cut to shape and size and used to seal off the bleeding area.
Med operacijo se obliži razrežejo v želeno obliko in velikost ter se uporabijo za prekritje krvavečega mesta.
For practical information about using Evarrest, patients should read the package leaflet or contact their doctor or pharmacist.
Za praktične informacije o uporabi zdravila Evarrest naj bolniki preberejo navodilo za uporabo ali se posvetujejo z zdravnikom ali farmacevtom.
Evarrest is made of absorbable material that can be left in the patients after surgery.
Zdravilo Evarrest je izdelano iz absorbilnega materiala, ki lahko po operaciji ostane v telesu bolnika.
Two studies compared Evarrest with commonly used surgical techniques considered to be standard care.
V dveh študijah so zdravilo Evarrest primerjali s kirurškimi tehnikami, ki veljajo za standardno oskrbo.
Evarrest is a surgical product used in adults to help stop bleeding during surgery when standard methods for controlling bleeding are not sufficient.
Evarrest je zdravilo za uporabo v kirurgiji, ki se uporablja pri odraslih za zaustavljanje krvavitev med operacijo, kadar standardne metode za obvladovanje krvavitev niso dovolj učinkovite.
For the full list of all side effects reported with Evarrest, see the package leaflet.
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Evarrest, glejte navodilo za uporabo.
Evarrest has been shown in studies to be effective in helping to stop bleeding during surgeries, with most patients having their bleeding stopped within 4 minutes.
Zdravilo Evarrest je v študijah učinkovito pomagalo zaustaviti krvavitve med operacijo, saj se je krvavitev pri večini bolnikov zaustavila v 4 minutah.
The complications that arise in patients being treated with Evarrest are generally related to the surgical procedure and the underlying conditions, and include post-surgery bleeding and increased fibrinogen levels in the blood.
Zapleti, ki se lahko pojavijo pri bolnikih, zdravljenih z zdravilom Evarrest, so običajno povezani s kirurškim posegom in obstoječimi boleznimi ter vključujejo krvavitev po operaciji in zvišane ravni fibrinogena v krvi.
When an Evarrest patch is applied to a bleeding area during surgery, the moisture causes the active substances to react together, leading to the rapid formation of clots.
Ko se zdravilo Evarrest med operacijo nanese na krvaveče mesto, vlaga povzroči, da zdravilni učinkovini reagirata med seboj in povzročita hitro tvorbo strdkov.
One study compared Evarrest with another product, Surgicel, in patients undergoing abdominal, thoracic and pelvic surgeries.
V eni študiji so zdravilo Evarrest primerjali z drugim zdravilom, Surgicel, pri bolnikih, ki so prestali operacijo trebuha, prsnega koša in medenice.
How is Evarrest used?
Kako se zdravilo Evarrest uporablja?
98% of the patients in the Evarrest group (59 out of 60) had their bleeding stopped within 4 minutes (with no recurrence of bleeding during a 6-minute observation period) compared with 53% of patients in the Surgicel group (16 out of 30).
V skupini bolnikov, ki so prejeli zdravilo Evarrest, se je krvavitev v 4 minutah zaustavila pri 98 % (59 od 60) bolnikov (krvavitev se med 6-minutnim opazovanjem ni ponovila), v skupini, ki je prejela zdravilo Surgicel, pa pri 53 % (16 od 30) bolnikov.
The complications seen in studies with Evarrest were generally related the surgical procedure and the underlying conditions although there were cases of re-bleeding from the sites where Evarrest patches were used.
Zapleti, ki so jih opazili med študijami z zdravilom Evarrest, so bili običajno povezani s kirurškim posegom in obstoječimi boleznimi, vendar pa so zabeležili tudi primere ponovne krvavitve na mestih, kjer so bili nameščeni obliži Evarrest.
Similar results were seen in a study in patients undergoing liver surgery: 83% of patients in the Evarrest group (33 out of 40) had their bleeding stopped within 4 minutes compared with 30% of the standard care group (13 out of 44).
Podobne rezultate so zabeležili tudi v študiji z bolniki, ki so prestali operacijo jeter: v skupini, ki je prejela zdravilo Evarrest, se je krvavitev v 4 minutah zaustavila pri 83 % (33 od 40) bolnikov, v skupini, ki je bila deležna standardne oskrbe pa pri 30 % (13 od 44) bolnikov.
In a study in patients undergoing abdominal, thoracic and pelvic surgeries, 84% of patients in the Evarrest group had their bleeding stopped within 4 minutes (50 out of 59) compared with 31% (10 out of 32) in the standard care group.
V študiji z bolniki, ki so prestali operacijo trebuha, prsnega koša in medenice, se je v skupini z zdravilom Evarrest krvavitev v 4 minutah zaustavila pri 84 % (50 od 59) bolnikov, v skupini s standardno oskrbo pa pri 31 % (10 od 32) bolnikov.
How does Evarrest work?
Kako zdravilo Evarrest deluje?
Packaging Content Package sizeWithdrawal period
Vsebina Velikost pakiranja
EU (MA) number
EU (MA) številka
The main measure of effectiveness was the number patients who had a complete response to treatment.
Glavno merilo učinkovitosti je bilo število bolnikov, ki so se popolnoma odzvali na zdravljenje.
The European Commission granted a conditional marketing authorisation valid throughout the European Union for Pixuvri on 10 May 2012.
Evropska komisija je pogojno dovoljenje za promet z zdravilom Pixuvri, veljavno po vsej Evropski uniji, odobrila dne 10. maja 2012.
The side effects of the medicine were considered to be short term and manageable.
Neželene učinke zdravila je opredelil kot kratkoročne in obvladljive.
It works by interfering with the DNA within cells, preventing them from making more copies of DNA and making proteins.
Deluje tako, da zavira DNK v celicah, s čimer jim prepreči kopiranje DNK in izdelavo beljakovin.
The full EPAR for Pixuvri can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Pixuvri je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
In addition, patients treated with Pixuvri lived for longer without their disease getting worse.
Poleg tega so bolniki, ki so se zdravili z zdravilom Pixuvri, živeli dlje, ne da bi se njihova bolezen poslabšala.
The recommended dose is 50 mg/m2 given as an infusion into a vein over at least 60 minutes on days 1, 8 and 15 of a 28-day cycle.
Priporočeni odmerek je 50 mg/m2 v najmanj 60-minutni infuziji v veno, ki jo bolnik dobi 1., 8. in 15. dan 28-dnevnega kroga zdravljenja.
This is a summary of the European public assessment report (EPAR) for Pixuvri.
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Pixuvri.
It must not be used in patients with severe liver problems and in patients whose bone marrow produces abnormally low levels of blood cells.
Ne smejo ga uporabljati bolniki, ki imajo hude težave z delovanjem jeter, in tisti, katerih kostni mozeg proizvaja neobičajno nizke ravni krvnih celic.
Every year, the European Medicines Agency will review any new information that may become available and this summary will be updated as necessary.
Evropska agencija za zdravila bo vsaj enkrat letno ponovno pregledala nove podatke o zdravilu in posodobila povzetek glavnih značilnosti zdravila, če bo potrebno.
The dose of Pixuvri is based on the patient's body surface area (calculated using the patient's height and weight).
Odmerek zdravila Pixuvri temelji na bolnikovi telesni površini (izračunani na podlagi njegove višine in mase).
The effects of Pixuvri were first tested in experimental models before being studied in humans.
Učinki zdravila Pixuvri so bili najprej preskušeni na poskusnih modelih, nato pa so jih raziskali pri ljudeh.
In patients who develop side effects or who have very low blood levels of neutrophils (a type of white blood cell that fights infection) and platelets (components that help the blood to clot), the dose may have to be reduced or treatment may have to be delayed.
Pri bolnikih, pri katerih nastopijo neželeni učinki ali ki imajo v krvi zelo nizke ravni nevtrofilcev (vrste belih krvnih celic, ki se borijo proti okužbam) in krvnih ploščic (komponent, ki pomagajo pri strjevanju krvi), bo morda treba zmanjšati odmerek ali odložiti zdravljenje.
For more information about treatment with Pixuvri, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Za več informacij o zdravljenju z zdravilom Pixuvri preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
The CHMP concluded that the benefits of Pixuvri are greater than its risks and recommended that it be given marketing authorisation.
Odbor CHMP je zaključil, da so koristi zdravila Pixuvri večje od z njim povezanih tveganj, in priporočil, da se zanj odobri dovoljenje za promet.
EPAR summary for the public pixantrone
Povzetek EPAR za javnost piksantron
It is available as a powder that is made up into a solution for infusion (a drip into a vein).
Na voljo je kot prašek za pripravo raztopine za infundiranje (kapalne infuzije v veno).
The most common side effects with Pixuvri (seen in more than 1 patient in 10) are neutropenia, leucopenia and lymphopenia (low levels of different types of white blood cells), thrombocytopenia (low levels of platelets in the blood), anaemia (low levels of red blood cells), nausea (feeling sick), vomiting, skin discolouration, hair loss, chromaturia (abnormal colouration of the urine) and asthenia (weakness).
Najpogostejši neželeni učinki zdravila Pixuvri (opaženi pri več kot 1 bolniku od 10) so nevtropenija, levkopenija in limfopenija (nizke ravni različnih vrst belih krvnih celic), trombocitopenija (nizke ravni krvnih ploščic), anemija (nizke ravni rdečih krvnih celic), navzeja (slabost), bruhanje, sprememba barve kože, izpadanje las, kromaturija (nenormalna obarvanost urina) in astenija (šibkost).
This means that there is more evidence to come about the medicine, in particular its benefits in patients who have previously been treated with rituximab.
To pomeni, da se pričakujejo dodatni dokazi o zdravilu, zlasti o njegovih koristih pri bolnikih, ki so se prej zdravili z rituksimabom.
This is a cancer of the lymph tissue (part of the immune system) that affects a type of white blood cell called B lymphocytes, or B cells.
To je rak limfnega tkiva (dela imunskega sistema), ki prizadene vrsto belih krvnih celic, imenovanih B-limfociti ali B-celice.
Other information about Pixuvri
Druge informacije o zdravilu Pixuvri
Patients receiving Pixuvri must not be given vaccines containing attenuated (weakened live) viruses.
Bolniki, ki se zdravijo z zdravilom Pixuvri, ne smejo dobiti cepiv z atenuiranimi (živimi oslabljenimi) virusi.
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Pixuvri.
Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil zdravilo Pixuvri, na podlagi česar je oblikoval mnenje za odobritev dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
Patients were given either six cycles of Pixuvri or another approved anticancer medicine chosen by their doctor.
Bolniki so prestali šest krogov zdravljenja z zdravilom Pixuvri ali drugim odobrenim zdravilom proti raku, ki ga je izbral njihov zdravnik.
What benefit has Pixuvri shown during the studies?
Kakšne koristi je zdravilo Pixuvri izkazalo med študijami?
Pixuvri was shown to be beneficial in patients with aggressive non-Hodgkin's B cell lymphoma: 20% of patients responded completely to Pixuvri (14 out of 70 patients) compared with 5.7% of patients receiving other agents (4 out of 70 patients).
Zdravilo Pixuvri je izkazalo koristen učinek pri bolnikih z agresivnim ne-Hodgkinovim B-celičnim limfomom: 20 % bolnikov se je popolnoma odzvalo na zdravljenje z zdravilom Pixuvri (14 od 70 bolnikov) v primerjavi s 5,7 % bolnikov, ki so dobivali druge učinkovine (4 od 70 bolnikov).
This means that the cancer cells in non-Hodgkin's B cell lymphoma cannot divide and eventually die.
To pomeni, da se rakaste celice neHodgkinovega B-celičnega limfoma ne morejo deliti in sčasoma odmrejo.
However, the Committee noted that more data were needed on the benefits of Pixuvri in patients who have received previous treatment with rituximab (another medicine commonly used to treat lymphoma).
Vendar je opozoril, da je potrebnih več podatkov o koristih zdravila Pixuvri pri bolnikih, ki so se prej zdravili z rituksimabom (drugim zdravilom, ki se pogosto uporablja za zdravljenje limfoma).
Pixuvri is used to treat adult patients with non-Hodgkin's B cell lymphoma.
Pixuvri se uporablja za zdravljenje odraslih bolnikov z ne-Hodgkinovim B-celičnim limfomom.
Pixuvri must be given by a doctor who has experience in the use of anticancer medicines and who has access to facilities for monitoring the patient.
Zdravilo Pixuvri sme dajati samo zdravnik, ki ima izkušnje z uporabo zdravil proti raku in ima dostop do opreme za spremljanje bolnikov.
Pixuvri can be given for up to six cycles.
Zdravilo Pixuvri se lahko uporablja v največ šestih krogih zdravljenja.
The active substance in Pixuvri, pixantrone, is a cytotoxic medicine (a medicine that kills cells that are dividing, such as cancer cells) that belongs to the group ‘anthracyclines'.
Zdravilna učinkovina v zdravilu Pixuvri, piksantron, je citotoksično zdravilo (zdravilo, ki uničuje celice, ki se delijo, na primer rakaste celice), ki spada v skupino „antraciklinov“.
What is the risk associated with Pixuvri?
Kakšna tveganja so povezana z zdravilom Pixuvri?
The company that makes Pixuvri will carry out a study to further investigate the effects of using Pixuvri in patients who had received prior treatment with rituximab.
Družba, ki izdeluje zdravilo Pixuvri, bo opravila študijo, s katero bo dodatno raziskala učinke zdravljenja z zdravilom Pixuvri pri bolnikih, ki so se prej zdravili z rituksimabom.
Pixuvri is used when the lymphoma is aggressive and has come back or has not responded to other chemotherapy treatments (medicines to treat cancer).
Zdravilo Pixuvri se uporablja, kadar je limfom agresiven in se je ponovil ali se ni odzval na zdravljenje z drugimi kemoterapevtiki (zdravili proti raku).
Pixuvri is a medicine that contains the active substance pixantrone.
Pixuvri je zdravilo, ki vsebuje zdravilno učinkovino piksantron.
For the full list of all side effects reported with Pixuvri, see the package leaflet.
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Pixuvri, glejte navodilo za uporabo.
Pixuvri must not be used in patients who are hypersensitive (allergic) to pixantrone or any of the other ingredients.
Zdravila Pixuvri ne smejo uporabljati osebe, ki so preobčutljive za (alergične na) piksantron ali katero koli drugo sestavino zdravila.
The CHMP also considered the seriousness of the disease and the lack of suitable alternative treatments for patients whose non-Hodgkin's B cell lymphoma has come back or has not responded to other chemotherapy treatments.
Odbor CHMP je upošteval tudi resnost bolezni in pomanjkanje ustreznih nadomestnih zdravil za bolnike, pri katerih se je neHodgkinov B-celični limfom ponovil ali se ni odzval na zdravljenje z drugimi kemoterapevtiki.
What information is still awaited for Pixuvri?
Katere informacije o zdravilu Pixuvri še pričakujemo?
The CHMP concluded that patients with aggressive non-Hodgkin's B cell lymphoma had a better response to treatment with Pixuvri than other cancer treatments.
Odbor CHMP je zaključil, da so se bolniki z agresivnim ne-Hodgkinovim B-celičnim limfomom bolje odzvali na zdravilo Pixuvri kot na druga zdravila proti raku.
Why has Pixuvri been approved?
Zakaj je bilo zdravilo Pixuvri odobreno?
What is Pixuvri used for?
Za kaj se zdravilo Pixuvri uporablja?
How has Pixuvri been studied?
Kako je bilo zdravilo Pixuvri raziskano?
What is Pixuvri?
Kaj je zdravilo Pixuvri?
Pixuvri was compared with other chemotherapy treatments in one main study involving 140 adults with aggressive non-Hodgkin's B cell lymphoma, who had previously received at least two other treatments, and whose cancer had come back or had not responded to treatment.
V eni glavni študiji, ki je zajela 140 odraslih z agresivnim ne-Hodgkinovim B-celičnim limfomom, ki so se predhodno zdravili z vsaj dvema drugima zdraviloma in pri katerih se je rak ponovil ali se ni odzval na zdravljenje, so zdravilo Pixuvri primerjali z drugimi kemoterapevtiki.
How is Pixuvri used?
Kako se zdravilo Pixuvri uporablja?
How does Pixuvri work?
Kako zdravilo Pixuvri deluje?
Pixuvri has been given ‘conditional approval'.
Zdravilo je pridobilo tako imenovano „pogojno dovoljenje za promet“.
The full EPAR and risk management plan summary for Pemetrexed medac can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Celotno evropsko javno poročilo o oceni zdravila (EPAR) in povzetek načrta obvladovanja tveganj za zdravilo Pemetreksed medac sta na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
What measures are being taken to ensure the safe and effective use of Pemetrexed medac?
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Pemetreksed medac?
The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Pemetrexed medac has been shown to be comparable to Alimta.
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da je bilo v skladu z zahtevami EU dokazano, da je zdravilo Pemetreksed medac primerljivo z zdravilom Alimta.
This is a summary of the European public assessment report (EPAR) for Pemetrexed medac.
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Pemetreksed medac.
The Committee recommended that Pemetrexed medac be approved for use in the EU.
Priporočil je, da se zdravilo Pemetreksed medac odobri za uporabo v EU.
This means that Pemetrexed medac is similar to a ‘reference medicine' already authorised in the European Union (EU) called Alimta.
To pomeni, da je podobno „referenčnemu zdravilu“, ki je že odobreno v Evropski uniji (EU), in sicer zdravilu Alimta.
Because Pemetrexed medac is a generic medicine, its benefits and risks are taken as being the same as the reference medicine's.
Ker je zdravilo Pemetreksed medac generično zdravilo, so njegove koristi in tveganja enaki kot pri referenčnem zdravilu.
What are the benefits and risks of Pemetrexed medac?
Kakšne so koristi in tveganja, povezani z zdravilom Pemetreksed medac?
Pemetrexed medac is a cancer medicine used to treat two types of lung cancer:
Zdravilo Pemetreksed medac je zdravilo za zdravljenje raka, ki se uporablja za zdravljenje dveh vrst pljučnega raka:
What is Pemetrexed medac and what is it used for?
Kaj je zdravilo Pemetreksed medac in za kaj se uporablja?
A risk management plan has been developed to ensure that Pemetrexed medac is used as safely as possible.
Za zagotovitev čim varnejše uporabe zdravila Pemetreksed medac je bil pripravljen načrt obvladovanja tveganj.
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Pemetrexed medac, including the appropriate precautions to be followed by healthcare professionals and patients.
V skladu s tem načrtom so bile v povzetek glavnih značilnosti zdravila in navodilo za njegovo uporabo vključene informacije o varnosti, vključno s previdnostnimi ukrepi, ki jih morajo upoštevati zdravstveni delavci in bolniki.
For practical information about using Pemetrexed medac, patients should read the package leaflet or contact their doctor or pharmacist.
Za praktične informacije o uporabi zdravila Pemetreksed medac naj bolniki preberejo navodilo za uporabo ali se posvetujejo z zdravnikom ali farmacevtom.
To reduce side effects, patients should take a corticosteroid (a type of medicine that reduces inflammation) and folic acid (a type of vitamin), and receive injections of vitamin B12 during treatment with Pemetrexed medac.
Da bi zmanjšali neželene učinke, morajo bolniki med zdravljenjem z zdravilom Pemetreksed medac jemati kortikosteroid (vrsto zdravila, ki ublaži vnetje) in folno kislino (vrsto vitamina) ter prejemati injekcije vitamina B12.
For more information about treatment with Pemetrexed medac, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Za več informacij o zdravljenju z zdravilom Pemetreksed medac preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
It is not intended to provide practical advice on how to use Pemetrexed medac.
Povzetek ni namenjen zagotavljanju praktičnih nasvetov o njegovi uporabi.
Pemetrexed medac is a ‘generic medicine'.
Zdravilo Pemetreksed medac je „generično zdravilo“.
Other information about Pemetrexed medac
Druge informacije o zdravilu Pemetreksed medac
When Pemetrexed medac is given with cisplatin, an ‘anti-emetic' medicine (to prevent vomiting) and fluids (to prevent dehydration) should also be given before or after the cisplatin dose.
Kadar se zdravilo Pemetreksed medac daje v kombinaciji s cisplatinom, je treba pred odmerkom cisplatina ali po njem bolniku dati tudi „antiemetično“ zdravilo (za preprečevanje bruhanja) in tekočino (za preprečevanje dehidracije).
The active substance in Pemetrexed medac, pemetrexed, is a cytotoxic medicine (a medicine that kills cells that are dividing, such as cancer cells), which belongs to the group ‘antimetabolites'.
Zdravilna učinkovina v zdravilu Pemetreksed medac, pemetreksed, je citotoksik (zdravilo, ki uničuje celice, ki se delijo, kot na primer rakave celice) iz skupine „antimetabolitov“.
Pemetrexed medac is available as a powder that is made up into a solution for infusion (drip) into a vein.
Zdravilo Pemetreksed medac je na voljo v obliki praška za pripravo raztopine za infundiranje (kapalna infuzija) v veno.
Pemetrexed medac pemetrexed
Pemetreksed medac pemetreksed
Why is Pemetrexed medac approved?
Zakaj je bilo zdravilo Pemetreksed medac odobreno?
Pemetrexed medac contains the active substance pemetrexed.
Zdravilo Pemetreksed medac vsebuje zdravilno učinkovino pemetreksed.
How has Pemetrexed medac been studied?
Kako je bilo zdravilo Pemetreksed medac raziskano?
How does Pemetrexed medac work?
Kako zdravilo Pemetreksed medac deluje?
No additional studies were needed as Pemetrexed medac is a generic medicine that is given by infusion and contains the same active substance as the reference medicine, Alimta.
Ker je zdravilo Pemetreksed medac generično zdravilo, ki se daje z infundiranjem in vsebuje isto zdravilno učinkovino kot referenčno zdravilo Alimta, niso bile potrebne nobene dodatne študije.
How is Pemetrexed medac used?
Kako se zdravilo Pemetreksed medac uporablja?
Results at week 16
Rezultati v 16. tednu
Outcomes a
Izid a